For more information on this report please contact [email protected] (+44 (0) 2075499976) or refer to our website: http://www.visiongain.com/Report/1126/World-Vaccines-Market-2013-2023
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Figure 7.11 Rest of the World Vaccines Market: Revenues ($m), 2012-2023
Figure 10.1 World Vaccines Market: Revenues ($m), 2012-2017
Figure 10.2 World Vaccines Market: Revenues ($m), 2018-2023
Figure 10.3 World Vaccines Market, Breakdown by Segment: Revenues ($m), 2012-2017
Figure 10.4 World Vaccines Market, Breakdown by Segment: Revenues ($m), 2018-2023
www.visiongain.com
Contents
Abbott Laboratories
Aaron Diamond AIDS Research Center
Abbott Laboratories
AbbVie
Acambis
ACE Biosciences
Activartis Biotech
Adamis Pharmaceuticals
Aduro BioTech
Advaxis
Aeras
Aeras Global TB Vaccine Foundation
Affiris
Agency for Science, Technology and Research (Singapore)
Agenus
Akela Pharma
ALK Abello
Allergy Therapeutics
Allertein Therapeutics
Alnylam
AlphaVax
Altravax
American Academy of Pediatrics
Amgen
Antigen Discovery
Antigen Express
Antigenics
Argos Therapeutics
Astellas Pharma
Organisations Mentioned in Report
www.visiongain.com
Contents AstraZeneca
Augmenta Biologicals
AuRx
AVAX Technologies
Baxter Healthcare
Bayer HealthCare
Bayhill Therapeutics
Beijing Key Yuan Xinhai Pharmaceutical
Beijing Vigoo Biological
Bellicum Pharmaceuticals
Bharat Biotech
Biken Japan
Bill & Melinda Gates Foundation
Bio-Manguinhos
BiondVax
Bionor Pharma
BioNTech
BioSante Pharmaceuticals
Biotech Synergy
Biovest International
BN ImmunoTherapeutics (Bavarian Nordic)
Boston Children's Hospital
BravoBio
Butantan
Cadila Pharma
Cancer Advances
Celldex Therapeutics
CEL-SCI
Celtic Pharma
Center of Molecular Immunology (Cuba)
www.visiongain.com
Contents Centers for Disease Control (CDC)
CG Therapeutics
Chemo-Sero-Therapeutic Research Institute
Chengdu Institute
China National Biotech Group (CNBG)
China NT Pharma Group
Chinese Centre for Disease Control
Chinese State Food and Drug Administration (SFDA)
Chiron
Circassia
Colby Pharmaceutical
Columbia University
Cosmo Pharmaceuticals
Crucell
CSL Biotherapies
Cuba’s Center of Molecular Immunology
CureVac
Cytokine PharmaSciences
Cytos Biotechnology
Daiichi Sankyo
DBV Technologies
Dendreon
Denka Seiken Company
Desmond Tutu TB Centre
Diabetes UK
Diamyd
Dynavax
DynPort Vaccine Company
Eisai
Elea Laboratories
www.visiongain.com
Contents EMD Serono
Emergent BioSolutions
Endocyte
Epeius Biotechnologies
Erasmus Medical Centre
Etubics
European Medicines Agency (EMA)
Evans Medical
Food and Drug Administration (US FDA)
Galena Biopharma
GAVI Alliance
GE Healthcare
GeneCure Biotechnologies
Genetic Immunity
Genocea Biosciences
GenPhar
GenVec
GeoVax Labs
Geron
GlaxoSmithKline (GSK)
Glide Pharma
Gliknik
Global Health Innovative Technology Fund (GHIT Fund)
GlobeImmune
Gradalis
Greer Laboratories
Hawaii Biotech
Health Protection Agency (HPA)
Heat Biologics
Helmholtz Centre for Infection Research
www.visiongain.com
Contents iBio
Ichor Medical Systems
immatics biotechnologies
Immune Response Biopharma
Immune Targeting Systems
Immunitor
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
Immunomic Therapeutics
Immunotope
Immunovaccine
Immunovative Therapies
ImmusanT
Infectious Diseases Research Institute
Inovio Pharmaceuticals
Intercell
Intercell USA
International AIDS Vaccine Initiative (IAVI)
International Federation of Pharma Manufacturers and Associations (IFPMA)
International Medica Foundation
Inviragen
J. Craig Venter Institute
Janssen Alzheimer Immunotherapy
JN-International Medical
Johnson & Johnson
Joint Committee on Vaccination and Immunisation (JCVI, UK)
KAEL-GemVax
Karolinska Institute
Kitasato Institute
www.visiongain.com
Contents Korean Ministry of Health and Welfare
La Jolla Institute for Allergy & Immunology
Life Technologies
LigoCyte Pharmaceuticals
Liquidia Technologies
London School of Hygiene and Tropical Medicine
MabVax Therapeutics
Max Planck Society
MaxCyte
Medecins Sans Frontieres (MSF)
Medicago
MedImmune
Memgen
Menarini
Merck & Co.
Merck Serono
Meridian Biosciences
Mitsubishi Tanabe Pharma
Momotaro-Gene
Nabi Biopharmaceuticals
NanoBio
Nanotherapeutics
National Administration of Medicines, Food and Medical Technology (ANMAT, Argentina)
Natrix Separations
NewLink Genetics
Northwest Biotherapeutics
Novadigm Therapeutics
Novartis
NovaRx
Novavax
www.visiongain.com
Contents Novo Energies
Nuron Biotech
NuVax Therapeutics
Nypro Healthcare
Okairos
OncoPep
Oncothyreon
Opal Therapeutics
Opexa Therapeutics
Opko Health
Optimer Pharmaceuticals
Orban Biotech
Oregon Health and Science University, Vaccine and Gene Therapy Institute
Oxford BioMedica
PaxVax
Petrovax
Pfizer
PharmAthene
Pique Therapeutics
Polynoma
Prima Biomed
Profectus Biosciences
Progenics Pharmaceuticals
Protein Sciences
PsiOxus Therapeutics
Quantum Immunologics
Quest PharmaTech
Sanaria
Sanofi
Sanofi Pasteur
www.visiongain.com
Contents Sarepta
SciVac
Scripps Research Institute
Selecta Biosciences
Serum Institute of India
Shanghai BravoBio
Shanghai Pharma
Shantha Biotech
Shionogi
Sinopharm Group
Sinovac Biotech
Soligenix
South African Tuberculosis Vaccine Initiative (SATVI)
Stallergenes
Stemline Therapeutics
Sumagen
Sunovion Pharmaceuticals
Takeda
TapImmune
TD Vaccines
Tekmira
Tesco
Tetragenetics
Teva Pharmaceutical industries
Theraclone Sciences
Thymon
Topaz Pharmaceuticals
Transgene
TVAX Biomedical
UK Joint Committee on Vaccination and Immunisation
www.visiongain.com
Contents UMN Pharma
UNICEF
United Biomedical
Universidad de Chile
Université Laval
University of Cape Town
University of Guelph
University of London
University of Minnesota's Centre for Infectious Disease Research and Policy
University of Queensland
University of Toronto
US National Biodefence Science Board
US Naval Medical Research Center
Utrecht University
Vaccine Research Center (NIAID)
Vaccine Technologies
Vaccinogen
Vakzine Projekt Management
Valneva
Vanderbilt University
Vaxart
Vaxin
VaxInnate
VaxOnco
Vical
Vivalis
Vodafone
Walter Reed Army Institute
World Health Organisation (WHO)
Xcellerex
www.visiongain.com
Contents Zhejiang Tianyuan
Zuellig Pharma
Page 105
www.visiongain.com
World Vaccines Market 2013-2023 phase 3 studies on the candidate, the largest of which is a head-to-head comparison of Gardasil
and V 503 in 14,000 women. Merck announced in 2013 it is extending the clinical trials of V503
since too few patients in the Gardasil arm of the trial have developed HPV infections. This implies
that there is no medical need to vaccinate against additional subtypes of HPV; Gardasil alone
appears to offer adequate protection.
5.3.1.4 GlaxoSmithKline and Merck to Continue Dominating this Space In addition to V503, Merck has an octavalent candidate VLP-based candidate, V502. This product
completed phase 1 studies, with a phase 2 trial being withdrawn prior to enrolment in 2012,
presumably because Merck’s R&D focus is on the more-advanced V503 candidate. Genticel is
developing a therapeutic vaccine, ProCervix, for high-risk HPV patients; Inovio also has a
therapeutic DNA vaccine candidate, VGX-3100, in development. These therapeutic vaccines are
dealt with in the following chapter. In terms of preventive vaccines, GlaxoSmithKline seems set to
remain the only challenger to Merck in the HPV space.
5.3.1.5 Gardasil’s Prospects Depend on its Successor Although Gardasil’s revenues will fluctuate, visiongain anticipates that the product broadly faces a
decline based on its relative maturity and the likelihood of competition from the V-503 follow-on. If
further clinical data shows no rationale for transitioning patients to the nine-valent franchise
extension, Gardasil may continue to enjoy market dominance. Visiongain’s prediction here is
based on the likelihood that clinical data will ultimately justify the transition to V-503, with
consequent cannibalisation of Gardasil revenues. By 2017, visiongain estimates these revenues
will decline to $1429m. By 2023, general substitution of V-503 will see Gardasil’s revenues fall to
$650m, visiongain believes. See Table 5.5, Table 5.6, and Figure 5.4.
5.3.2 GlaxoSmithKline Continues to Dominate Hepatitis Vaccine Space GlaxoSmithKline’s hepatitis vaccines account for ~85% of the hepatitis vaccines market. As noted,
hepatitis B is widely included in paediatric combinations. Of GlaxoSmithKline’s other vaccines,
Twinrix offers inoculation against hepatitis A and hepatitis B to patients 18 years of age or over,
and comes in preservative-free liquid form for intramuscular injection. GlaxoSmithKline also
markets separate vaccines for hepatitis A (Havrix) and hepatitis B (Engerix-B, a recombinant
subunit vaccine supplied in refrigerated, preservative-free liquid form or in pre-filled syringes, and
its reformulation Fendrix for patients aged 15 years or over).